Ovarian cancer is the seventh most common cancer in women worldwide and the eighth most common cause of cancer death. Due to the lack of effective early detection strategies and the unspecific onset of symptoms, it is diagnosed at an advanced stage in 75% of cases. The cancer antigen (CA) 125 is used as a prognostic marker and its level is elevated in more than 85% of women with advanced stages of epithelial ovarian cancer (EOC). The standard treatment is primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT), but the later approach is neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). Several studies have been conducted to find out whether preoperative CA-125 serum levels influence treatment choice, surgical resection and survival outcome. The aim of our study was to analyse experience of single institution as Cancer comprehensive center with preoperative usefulness of CA-125.

中文翻译：

---

术前血清 CA-125 水平作为晚期上皮性卵巢癌患者细胞减灭程度的预测因子

卵巢癌是全球女性第七大常见癌症，也是癌症死亡的第八大常见原因。由于缺乏有效的早期检测策略和症状发作的不特异性，75% 的病例被诊断为晚期。癌症抗原 (CA) 125 被用作预后标志物，其水平在超过 85% 的晚期上皮性卵巢癌 (EOC) 女性中升高。标准治疗是初次减瘤手术 (PDS) 后进行辅助化疗 (ACT)，但后期方法是新辅助化疗 (NACT) 后进行间隔减瘤手术 (IDS)。已经进行了几项研究来确定术前 CA-125 血清水平是否影响治疗选择、手术切除和生存结果。